Neuphoria Therapeutics Inc. (NEUP)Healthcare | Biotechnology | Millis, United States | NasdaqGM
3.39 USD
+0.07
(2.108%)
⇧
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 1:49 a.m. EDT
The immediate outlook is clouded by significant legal overhangs, with multiple shareholder class-action investigations alleging unfair pricing practices, which creates substantial uncertainty for near-term liquidity and sentiment. While the stock recently staged a massive recovery from a 94% drop in 2024 to surge 440% in 2025, the current price action shows a distinct lack of follow-through, trading well below both the 50-day and 200-day moving averages and drifting lower over the last two weeks. This suggests the recent rally may be exhausting rather than establishing a new trend. Fundamentally, the business remains in a precarious state with negative earnings, negative free cash flow, and no revenue generation, relying entirely on capital markets for survival. There is no dividend to provide income, and the balance sheet, while currently showing low debt relative to equity, is typical of a pre-revenue biotech firm where cash burn is the primary constraint. The combination of active litigation, weak technical momentum, and a lack of commercial traction makes this a speculative hold at best, with limited catalysts for a sustained upward move in the near term. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.021595 |
| AutoARIMA | 0.023134 |
| MSTL | 0.025831 |
| AutoTheta | 0.133519 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 6.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.751 |
| Excess Kurtosis | -0.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.14 |
| Revenue per Share | 0.267 |
| Market Cap | 18,344,422 |
| Forward P/E | -1.38 |
| Previous Name | Bionomics Limited |
| Website | https://www.neuphoriatx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8074246 |
| Address1 | 14 Milliston Road |
| Address2 | Box 195 |
| All Time High | 264.0 |
| All Time Low | 2.124 |
| Ask | 3.96 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 11,780 |
| Average Daily Volume3 Month | 162,988 |
| Average Volume | 162,988 |
| Average Volume10Days | 11,780 |
| Bid | 3.89 |
| Bid Size | 1 |
| Book Value | 4.546 |
| City | Millis |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.39 |
| Current Ratio | 27.847 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.49 |
| Day Low | 3.32 |
| Debt To Equity | 0.14 |
| Display Name | Neuphoria Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,742,212,800 |
| Earnings Timestamp Start | 1,741,863,540 |
| Ebitda | -8,346,621 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.178 |
| Enterprise To Revenue | -1.266 |
| Enterprise Value | -1,486,763 |
| Eps Current Year | -2.43 |
| Eps Forward | -2.46 |
| Eps Trailing Twelve Months | -3.06 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.731 |
| Fifty Day Average Change | -0.34099984 |
| Fifty Day Average Change Percent | -0.09139637 |
| Fifty Two Week Change Percent | -80.74246 |
| Fifty Two Week High | 17.9 |
| Fifty Two Week High Change | -14.509999 |
| Fifty Two Week High Change Percent | -0.8106145 |
| Fifty Two Week Low | 3.19 |
| Fifty Two Week Low Change | 0.20000005 |
| Fifty Two Week Low Change Percent | 0.062695935 |
| Fifty Two Week Range | 3.19 - 17.9 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,639,665,000,000 |
| Float Shares | 5,371,994 |
| Forward Eps | -2.46 |
| Forward P E | -1.3780488 |
| Free Cashflow | -8,339,007 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1 |
| Fullday Change | 0.07000017 |
| Fullday Change Percent | 2.1406782 |
| Fullday Price | 3.39 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 1,174,165 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05019 |
| Held Percent Institutions | 0.43338 |
| Implied Shares Outstanding | 5,411,334 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.bionomics.com.au/page.php?section=34 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,782,777,600 |
| Last Split Date | 1,734,998,400 |
| Last Split Factor | 1:12 |
| Long Business Summary | Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts. |
| Long Name | Neuphoria Therapeutics Inc. |
| Market | us_market |
| Market Cap | 18,344,422 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_3331473 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -13,451,931 |
| Next Fiscal Year End | 1,814,313,600 |
| Non Diluted Market Cap | 19,913,709 |
| Open | 3.49 |
| Operating Cashflow | -12,353,074 |
| Operating Margins | -0.15664 |
| Payout Ratio | 0.0 |
| Phone | 339 240 6066 |
| Prev Name | Bionomics Limited |
| Previous Close | 3.32 |
| Price Eps Current Year | -1.3950617 |
| Price Hint | 4 |
| Price To Book | 0.74571055 |
| Price To Sales Trailing12 Months | 15.623377 |
| Profit Margins | 0.0 |
| Quick Ratio | 27.332 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0700002 |
| Regular Market Change Percent | 2.10844 |
| Regular Market Day High | 3.49 |
| Regular Market Day Low | 3.32 |
| Regular Market Day Range | 3.32 - 3.49 |
| Regular Market Open | 3.49 |
| Regular Market Previous Close | 3.32 |
| Regular Market Price | 3.39 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 26,636 |
| Return On Assets | -0.19655001 |
| Return On Equity | -0.61702 |
| Revenue Per Share | 0.267 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 5,411,334 |
| Shares Percent Shares Out | 0.0037 |
| Shares Short | 20,022 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 64,641 |
| Short Name | Neuphoria Therapeutics Inc. |
| Short Percent Of Float | 0.0037 |
| Short Ratio | 1.11 |
| Source Interval | 15 |
| State | MA |
| Symbol | NEUP |
| Total Cash | 19,865,532 |
| Total Cash Per Share | 3.671 |
| Total Debt | 34,345 |
| Total Revenue | 1,174,165 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.205635 |
| Two Hundred Day Average Change | -0.81563497 |
| Two Hundred Day Average Change Percent | -0.1939386 |
| Type Disp | Equity |
| Volume | 26,636 |
| Website | https://www.neuphoriatx.com |
| Zip | 2,054 |